b1427ebee7be51.rf98EvjW5M2G8MvbHO_z-XcsJIptfDI1AFwaR40f2E0.wpU9cLuR1ofZwvusVdijsTh8beMZD2VCdwUsNLxZ7yfMthVTyuGO_-OZjg
11-16 CSPC Pharma Starts Phase Ib/II Trial of Cancer Drug Combination in China MT
11-06 CSPC Pharma Begins Trial of Pulmonary Fibrosis Drug in China MT
11-06 CSPC Pharma Begins Trial of B-cell non-Hodgkin Lymphoma Drug in China MT
11-06 CSPC Pharmaceutical Group Limited Initiates Phase I/II Clinical Trial of SYS6055 Injection for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma at First Centre in China CI
11-05 CSPC Pharmaceutical Starts Phase I/II Trial of Experimental Cancer Drug MT
11-05 CSPC Pharmaceutical Group Limited Initiates Phase I/II Clinical Trial Of SYS6062 For Treatment Of Advanced Solid Tumours In China CI
11-03 CSPC Pharma Begins Trial of Hypertension Drug in China MT
11-03 CSPC Pharma Begins Tumor Drug Trial in China MT
11-03 CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial of SYH2072 Tablets for Treatment of Uncontrolled Hypertension and Resistant Hypertension at First Centre in China CI
11-02 CSPC Pharma Begins Two Vaccine Trials in China MT
11-02 CSPC Pharma Gets Positive Results from Triple Combination Regimen Trial for Diabetes Mellitus MT
11-02 CSPC Pharmaceutical Group Limited Announces Positive Topline Results From Phase III Clinical Trial Of Prusogliptin Tablets In Combination With Dapagliflozin Tablets And Metformin Hydrochloride Extended-Release Tablets For The Treatment Of Type 2 Diabetes Mellitus CI
11-02 CSPC Pharmaceutical Group Limited Announces Phase I/II Clinical Trial of SYS6052 (Recombinant Herpes Zoster Virus Vaccine (Cho Cells)) Officially Initiated in China CI
11-02 CSPC Pharmaceutical Group Limited Announces Phase I Clinical Trial of SYS6057 (Recombinant Respiratory Syncytial Virus Vaccine (Cho Cells)) Officially Initiated in China CI
10-30 CSPC Pharma Begins Trial of Advanced Solid Tumor Drug in China MT
10-30 CSPC Pharmaceutical Starts Phase I/II Trial of B7-H3 Cancer Drug in China MT
10-30 CSPC Pharmaceutical Group Limited Initiates Phase I/II Clinical Trial Of SYS6043 For The Treatment Of Advanced Solid Tumours At The First Centre In China CI
10-28 CSPC Pharmaceutical Begins Phase 1 Trial of Tumor Drug in China MT
10-28 CSPC Pharmaceutical Group Limited Initiates Phase I Clinical Trial of SYS6077 Injection for Advanced Malignant Tumours in China CI
10-27 CSPC Pharma Presents Results of Tumor Drug Studies at ESMO Congress 2026 MT
10-27 CSPC Pharmaceutical Group Limited Presents Results From Phase I/II Clinical Study of SYS6043 (B7-H3 ADC) for Advanced Breast Cancer at ESMO Congress 2026 CI
10-27 CSPC Pharmaceutical Group Limited Presents Results From Phase I/II Clinical Study Of Anti-PD-1/IL-15 Bifunctional Fusion Protein SYS6090 Monotherapy In Advanced Solid Tumours At ESMO Congress 2026 CI
10-26 CSPC Pharmaceutical Says Breast Cancer Drug Combo Cuts Progression Risk 54% in Phase III Trial MT
10-26 Cspc Pharmaceutical Group Limited and Jiangsu Alphamab Oncology Co., Ltd. Present Interim Analysis Results from Phase III0 Healer Clinical Study of Anbenitamab Injection Plus HB1801 for Her2-Positive Advanced Breast Cancer CI
10-26 CSPC Pharmaceutical Group Limited And Jiangsu Alphamab Oncology Co., Ltd. Present Updated Overall Survival Analysis Results From Phase III Clinical Study Of Anbenitamab Injection At ESMO Congress 2026 CI

Become a member to access more news

New member
No results match your criteria
  1. Stock Market
  2. Stocks
  3. 1093 Stock
  4. News CSPC Pharmaceutical Group Limited